KTTA - הכנסה תפעולית לפני ניכוי פחת Pasithea Therapeutics Corp.

Pasithea Therapeutics (KTTA) generates revenue through the operations of specialized ketamine infusion therapy centers. The EBITDA distribution across periods confirms the current financial momentum, where the value of 0.00 reflects this status. The company's prospects rely on the launch of small molecule trials in neurobiology and oncology. High human capital potential is secured by attracting schizophrenia experts through an RSU and options system.

This metric measures net cash flow from operating activities before taxes and depreciation, allowing for an assessment of the real efficiency of operational processes excluding accounting write-offs. Given the conservative management of clinical programs at Pasithea Therapeutics (KTTA), the EBITDA trend serves as the primary tool for monitoring spending discipline, identifying accidental cash spikes unrelated to fundamental business growth.